EF1α Promoter Lentiviral Vector for ALD Gene Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current gene therapy methods for adrenoleukodystrophy (ALD) using viral vectors have low efficiency and primarily modify blood stem cells, resulting in inadequate therapeutic effects due to suboptimal gene transfer and expression of the ABCD1 gene, necessitating improved viral gene transfer efficiency and broader stem cell modification.

Innovation Solution

An optimized lentiviral vector system utilizing an EF1α promoter and the NHP/TYF lentiviral vector system is employed for efficient gene transfer into autologous hematopoietic and mesenchymal stem cells, enhancing ABCD1 gene expression and stability, with the option for direct intracerebral injection, and dual stem cell line treatment approach.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional viral vectors are used for gene transfer, then gene delivery can be achieved, but gene transfer efficiency is low and therapeutic effect is insufficient

Engineering Contradiction:

Improvegene transfer efficiencyVSAvoidtherapeutic effect

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent optimizes multiple parameters of the lentiviral vector system including the promoter (EF1α), packaging cells, and purification conditions to maximize gene transfer efficiency. By systematically adjusting these parameters, the invention achieves significantly improved transduction efficiency compared to conventional vectors, directly addressing the productivity- reliability contradiction.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces optimized packaging cells as intermediaries to facilitate efficient gene transfer. These specialized packaging cells serve as a bridge between the lentiviral vector and target stem cells, enabling high-efficiency transduction while maintaining safety, thus resolving the contradiction between transfer efficiency and therapeutic reliability.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If only hematopoietic stem cells are modified, then gene therapy can be delivered, but the scope of treatment is limited and therapeutic effect is insufficient

Engineering Contradiction:

Improvescope of stem cell modificationVSAvoidclinical therapeutic effect

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The optimized lentiviral vector system demonstrated in the patent exhibits universal applicability across multiple stem cell types including hematopoietic stem cells, mesenchymal stem cells, and neural stem cells. This multi-functionality allows the same vector system to effectively transduce diverse cell types, expanding the scope of treatment while maintaining reliable therapeutic effects.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs a segmented approach by targeting and modifying multiple distinct stem cell populations (hematopoietic, mesenchymal, and neural stem cells) rather than relying on a single cell type. This segmentation strategy ensures comprehensive coverage of affected tissues and organs, thereby improving overall therapeutic reliability.

Inventive Principle:

Principle #1Segmentation

3Quantity of substance

If ABCD1 gene expression is low in stem cells, then gene transfer can be achieved, but VLCFA accumulation cannot be effectively removed

Engineering Contradiction:

ImproveABCD1 gene expression levelVSAvoidVLCFA removal efficiency

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent utilizes the EF1α promoter and optimizes transduction conditions to achieve high-level ABCD1 gene expression in stem cells. By controlling expression parameters, the invention ensures sufficient enzyme production to effectively remove accumulated VLCFA, resolving the contradiction between gene expression quantity and metabolic productivity.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method significantly increases ABCD1 gene expression levels in stem cells, achieving higher transfection efficiency, stability, and safety, leading to improved therapeutic outcomes for ALD by enabling stable and massive gene expression in both hematopoietic and mesenchymal stem cells, thus enhancing symptom relief and durability of gene treatment.

Implementation Method 1

transfecting autologous hematopoietic stem cells (HSCs) of a patient with an improved and optimized lentiviral vector carrying an ABCD1 gene

Methodology Applied

Scientific EffectLentiviral transduction:

Implementation Method 2

an ABCD1 gene under an EF1α promoter

Methodology Applied

Scientific EffectPromoter-driven transcription:

Data Source

PatentUS12065662B2Application of lentiviral vector EF1α promoter for optimising ABCD1 gene expression to treat adrenoleukodystrophy

Publication Date: 2024.08.20 CHENGDU YOUWA BIOTECH CO LTD

AI summary

Provided is a lentiviral vector comprising an EF1α promoter, a normal ABCD1 gene and an NHP/TYF lentiviral vector system, said vector being used for treating adrenoleukodystrophy. The present invention uses transfection into autologous haematopoietic stem cells (HSCs), for ALD gene therapy after being returned, which may be performed in combination with direct intracerebral injection of the lentiviral vector carrying the ABCD1 gene according to the actual circumstances.